{"id":"high-dose-corticosteroid","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Immunosuppression/increased infection risk"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Mood disturbances"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Corticosteroids bind to glucocorticoid receptors in the cytoplasm, translocating to the nucleus to modulate gene expression. This leads to decreased production of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), reduced immune cell proliferation and migration, and suppression of both innate and adaptive immune responses. High doses amplify these immunosuppressive effects.","oneSentence":"High-dose corticosteroids suppress immune system activity by inhibiting inflammatory cytokine production and reducing immune cell activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:48.992Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe inflammatory or autoimmune conditions (specific indication unknown from phase 3 context)"}]},"trialDetails":[{"nctId":"NCT07494084","phase":"PHASE4","title":"Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","status":"NOT_YET_RECRUITING","sponsor":"Washington State University","startDate":"2026-05-01","conditions":"Shift Work Schedule, Circadian Rhythm, Insulin Resistance","enrollment":24},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT06365853","phase":"PHASE2","title":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-29","conditions":"Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive","enrollment":100},{"nctId":"NCT05123040","phase":"PHASE1, PHASE2","title":"Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-06-05","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT06936566","phase":"PHASE2","title":"MAGIC Ruxolitinib for aGVHD","status":"RECRUITING","sponsor":"John Levine","startDate":"2025-05-14","conditions":"Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects","enrollment":98},{"nctId":"NCT05345847","phase":"NA","title":"Steroid Sparing in Immune Related Hepatitis (irH)","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2025-12-08","conditions":"Hepatitis Immune","enrollment":56},{"nctId":"NCT06750289","phase":"PHASE3","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-28","conditions":"Eosinophilic Asthma","enrollment":400},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT06780098","phase":"PHASE2","title":"Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-28","conditions":"Lung Neoplasm","enrollment":144},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07287397","phase":"PHASE1, PHASE2","title":"Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS","status":"RECRUITING","sponsor":"Vector Y Therapeutics","startDate":"2025-12-19","conditions":"Amyotrophic Lateral Sclerosis","enrollment":12},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT05811351","phase":"PHASE2","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-06","conditions":"Geographic Atrophy","enrollment":305},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT06419413","phase":"","title":"A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-01-08","conditions":"Asthma","enrollment":355},{"nctId":"NCT07100990","phase":"PHASE3","title":"Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-07-11","conditions":"Optic Neuritis, Myelitis, Myelitis, Transverse","enrollment":382},{"nctId":"NCT06917937","phase":"NA","title":"The Additive Effect of Exercise in Addition to Corticosteroid Injection in Plantar Fasciitis","status":"COMPLETED","sponsor":"Kutahya Health Sciences University","startDate":"2018-09-16","conditions":"Plantar Fascitis","enrollment":40},{"nctId":"NCT07448493","phase":"","title":"Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Gastric Cancer, Esophageal Cancer, Brain Metastases","enrollment":230},{"nctId":"NCT06932263","phase":"PHASE2","title":"Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-26","conditions":"Asthma","enrollment":540},{"nctId":"NCT07448662","phase":"","title":"Local Treatment Strategies for Brain Metastases of Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Colorectal Cancer, Brain Metastases, Adult","enrollment":700},{"nctId":"NCT05679401","phase":"PHASE3","title":"A Study With Imlifidase in Anti-GBM Disease","status":"TERMINATED","sponsor":"Hansa Biopharma AB","startDate":"2022-12-22","conditions":"Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome","enrollment":50},{"nctId":"NCT06594068","phase":"PHASE4","title":"Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-16","conditions":"Systemic Lupus Erythematosus","enrollment":16},{"nctId":"NCT06948396","phase":"","title":"Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-25","conditions":"Asthma","enrollment":300},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT06888817","phase":"PHASE3","title":"Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2025-06-19","conditions":"Radiation Necrosis, High Grade Glioma (III or IV), Brain Metastasases","enrollment":408},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT05653349","phase":"PHASE3","title":"Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-03","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":226},{"nctId":"NCT07216690","phase":"PHASE2","title":"Pregnenolone as a Treatment for Cannabis Intoxication","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04-01","conditions":"Cannabis Intoxication","enrollment":20},{"nctId":"NCT05440851","phase":"NA","title":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-30","conditions":"Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High","enrollment":6250},{"nctId":"NCT07420296","phase":"PHASE4","title":"Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-01-01","conditions":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":198},{"nctId":"NCT07399717","phase":"NA","title":"Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"Anabio R&D","startDate":"2026-01-26","conditions":"Pneumonia, Pneumonia in Children","enrollment":330},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT07362914","phase":"PHASE3","title":"Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-07","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT07337772","phase":"NA","title":"Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2026-02-01","conditions":"Adrenal Cortex Hormones, Arthroplasty, Replacement, Knee, Anesthesia, Local","enrollment":120},{"nctId":"NCT07328035","phase":"","title":"Remission in Adults With Severe Asthma in Thailand","status":"NOT_YET_RECRUITING","sponsor":"Thammasat University","startDate":"2026-01-01","conditions":"Severe Asthma, Asthma Control Level","enrollment":230},{"nctId":"NCT07309952","phase":"PHASE2","title":"Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Yang Hong","startDate":"2025-12-31","conditions":"Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer","enrollment":28},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT07262957","phase":"PHASE4","title":"Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2025-09-01","conditions":"Pancreas Head Cancer, Pancreas Adenocarcinoma, IPMN, Pancreatic","enrollment":400},{"nctId":"NCT06029595","phase":"PHASE2","title":"Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-11-26","conditions":"Uncontrolled Asthma","enrollment":517},{"nctId":"NCT05274815","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-17","conditions":"Asthma","enrollment":305},{"nctId":"NCT05643638","phase":"PHASE2","title":"A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD","status":"RECRUITING","sponsor":"Cynata Therapeutics Limited","startDate":"2024-03-04","conditions":"Graft Versus Host Disease, Acute","enrollment":60},{"nctId":"NCT04817189","phase":"PHASE4","title":"Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2021-02-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":414},{"nctId":"NCT06047171","phase":"PHASE2","title":"Rescue of Nephrons With ALE.F02 (RENAL-F02)","status":"RECRUITING","sponsor":"Alentis Therapeutics AG","startDate":"2023-09-07","conditions":"Glomerulonephritis Rapidly Progressive","enrollment":80},{"nctId":"NCT04744116","phase":"EARLY_PHASE1","title":"Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease","enrollment":24},{"nctId":"NCT06453694","phase":"PHASE2","title":"Efgartigimod for the Treatment of Acute Optic Neuritis","status":"RECRUITING","sponsor":"Anastasia Vishnevetsky, MD, MPH","startDate":"2025-08-12","conditions":"Optic Neuritis","enrollment":20},{"nctId":"NCT06795906","phase":"PHASE1","title":"A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-01-28","conditions":"Asthma","enrollment":24},{"nctId":"NCT05276492","phase":"PHASE1","title":"Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2023-01-24","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm","enrollment":50},{"nctId":"NCT03784781","phase":"","title":"Type 2 Innate Lymphoid Cells in Severe Pediatric Asthma","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-06-09","conditions":"Severe Asthma","enrollment":""},{"nctId":"NCT07192016","phase":"PHASE4","title":"129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":60},{"nctId":"NCT03373045","phase":"","title":"Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-02-27","conditions":"Asthma","enrollment":18},{"nctId":"NCT07175948","phase":"","title":"Outcome of Clinical Phenotypes of Pediatric Myocarditis at Assiut University Children Hospital","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-06-01","conditions":"Myocarditis, Myocarditis Acute","enrollment":100},{"nctId":"NCT04983888","phase":"PHASE2","title":"Obinutuzumab in Primary FSGS","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-11-17","conditions":"Primary Focal Segmental Glomerulosclerosis","enrollment":20},{"nctId":"NCT05919394","phase":"PHASE4","title":"Triple vs High Dose Inhaled CORticosteroids","status":"WITHDRAWN","sponsor":"Galaxia Empírica","startDate":"2023-06-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT05292586","phase":"PHASE3","title":"A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-08-31","conditions":"Asthma","enrollment":1377},{"nctId":"NCT04643158","phase":"PHASE2","title":"Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-03-12","conditions":"Asthma","enrollment":72},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04053634","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-26","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":689},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT05197842","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2022-02-22","conditions":"ANCA-associated Vasculitis","enrollment":93},{"nctId":"NCT01718197","phase":"","title":"Severe Asthma Research Program (SARP)- San Francisco Clinical Site","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-11","conditions":"Asthma","enrollment":151},{"nctId":"NCT02103348","phase":"","title":"Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2015-09","conditions":"Asthma","enrollment":25},{"nctId":"NCT05150704","phase":"PHASE3","title":"MYTHS - MYocarditis THerapy With Steroids","status":"RECRUITING","sponsor":"Niguarda Hospital","startDate":"2021-10-07","conditions":"Myocarditis Acute","enrollment":288},{"nctId":"NCT05757583","phase":"","title":"Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-04-05","conditions":"Asthma","enrollment":80},{"nctId":"NCT07074951","phase":"NA","title":"Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2013-03-10","conditions":"Primary IgA-nephropathy, High-risk, Caucasians","enrollment":240},{"nctId":"NCT04372615","phase":"PHASE2","title":"The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-03-30","conditions":"Autoimmune Encephalitis, Encephalitis","enrollment":116},{"nctId":"NCT05819541","phase":"PHASE2","title":"Treating Exacerbations of Asthma With Oral Montelukast in Children","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-10-20","conditions":"Status Asthmaticus","enrollment":90},{"nctId":"NCT02357472","phase":"NA","title":"The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders","status":"TERMINATED","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2014-01-01","conditions":"Infertility","enrollment":60},{"nctId":"NCT07030881","phase":"NA","title":"Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-06-20","conditions":"Asthma, COPD","enrollment":380},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":112},{"nctId":"NCT05414201","phase":"PHASE4","title":"A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-07-07","conditions":"Non-infectious Intermediate Posterior- or Pan-uveitis","enrollment":87},{"nctId":"NCT00859781","phase":"PHASE2","title":"177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2009-06","conditions":"Prostate Cancer","enrollment":55},{"nctId":"NCT03952559","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-05-24","conditions":"Atopic Dermatitis","enrollment":516},{"nctId":"NCT03811366","phase":"NA","title":"Multimodal Analysis and Electroretinogram in VKH From Acute Onset - Part I","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2011-06-01","conditions":"Uveomeningoencephalitic Syndrome, Inflammation, Choroid Disease","enrollment":12},{"nctId":"NCT03692676","phase":"","title":"Characteristics of Pts Initiating Spiriva Respimat in Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-05","conditions":"Asthma","enrollment":116133},{"nctId":"NCT04702022","phase":"NA","title":"Added Value of 18 FDG Pet-scanner in Diagnosis and Management of Subclinical Rejection in Kidney Transplant Patients","status":"RECRUITING","sponsor":"University of Liege","startDate":"2021-01-04","conditions":"Kidney Transplant Rejection, Kidney Transplant; Complications","enrollment":50},{"nctId":"NCT05061771","phase":"PHASE3","title":"Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)","status":"WITHDRAWN","sponsor":"AKARI Therapeutics","startDate":"2022-05-06","conditions":"Bullous Pemphigoid","enrollment":""},{"nctId":"NCT05403359","phase":"","title":"StEroids in hospitaLized patiEnts With Covid-19 in The Netherlands.","status":"COMPLETED","sponsor":"Henrik Endeman","startDate":"2022-06-01","conditions":"COVID-19","enrollment":2465},{"nctId":"NCT04662723","phase":"PHASE4","title":"Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.","status":"RECRUITING","sponsor":"Fondazione Schena","startDate":"2023-05-01","conditions":"Glomerulonephritis, Immunoglobulin A Nephropathy","enrollment":878},{"nctId":"NCT05707156","phase":"","title":"Prospective Observational Study on the Incidence of Opportunistic Fungal Infections","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-07-05","conditions":"Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis","enrollment":12032},{"nctId":"NCT06552364","phase":"PHASE4","title":"Air Pollution and Inhaled Corticosteroids in COPD","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-04-01","conditions":"COPD","enrollment":48},{"nctId":"NCT02649790","phase":"PHASE1, PHASE2","title":"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2016-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":277},{"nctId":"NCT02222155","phase":"PHASE2","title":"Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-04","conditions":"ANCA-associated Vasculitis","enrollment":42},{"nctId":"NCT02921555","phase":"PHASE4","title":"Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis","status":"TERMINATED","sponsor":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","startDate":"2018-10-11","conditions":"Ulcerative Colitis","enrollment":75},{"nctId":"NCT06833814","phase":"PHASE4","title":"DOSE Trial: Optimal Dose of Oral Corticosteroids to Treat Asthma Exacerbations","status":"NOT_YET_RECRUITING","sponsor":"Andréanne Côté","startDate":"2025-02-17","conditions":"Asthma Exacerbations","enrollment":36},{"nctId":"NCT06756061","phase":"PHASE2","title":"Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity","status":"RECRUITING","sponsor":"Byung-Sik Cho","startDate":"2025-01-15","conditions":"GVHD - Graft-Versus-Host Disease, Neoplasms, Haematopoietic Stem Cell Transplantation","enrollment":88},{"nctId":"NCT01396278","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":9},{"nctId":"NCT04159519","phase":"PHASE4","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-27","conditions":"Asthma, Severe Eosinophilic Asthma","enrollment":170},{"nctId":"NCT06693362","phase":"PHASE1","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-20","conditions":"Severe Viral Pneumonia(Not Include COVID-19)","enrollment":60},{"nctId":"NCT01084096","phase":"NA","title":"Trial of the Use of Antenatal Corticosteroids in Developing Countries","status":"COMPLETED","sponsor":"NICHD Global Network for Women's and Children's Health","startDate":"2011-10","conditions":"Preterm Birth","enrollment":103117},{"nctId":"NCT05476770","phase":"PHASE1","title":"Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies","status":"RECRUITING","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2022-11-11","conditions":"Hematologic Malignancy, AML, ALL","enrollment":54},{"nctId":"NCT03564236","phase":"NA","title":"Nasal High-Flow in COPD","status":"RECRUITING","sponsor":"Marieke Duiverman","startDate":"2018-10-01","conditions":"COPD Exacerbation","enrollment":136},{"nctId":"NCT03861455","phase":"PHASE2","title":"Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2019-07-15","conditions":"Chronic Hand Eczema","enrollment":94},{"nctId":"NCT06697535","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)","status":"RECRUITING","sponsor":"Guangzhou JOYO Pharma Co., Ltd","startDate":"2023-05-24","conditions":"Neuromyelitis Optica Spectrum Disorders","enrollment":35},{"nctId":"NCT05714670","phase":"PHASE2","title":"The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-04-01","conditions":"Lupus Nephritis, SLE Nephritis","enrollment":72},{"nctId":"NCT05018598","phase":"PHASE4","title":"Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-25","conditions":"Asthma","enrollment":320},{"nctId":"NCT01763580","phase":"PHASE4","title":"A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2012-07-16","conditions":"MCNS, Minimal Change Nephrotic Syndrome (MCNS)","enrollment":144}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1171,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"High Dose Corticosteroid","genericName":"High Dose Corticosteroid","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose corticosteroids suppress immune system activity by inhibiting inflammatory cytokine production and reducing immune cell activation. Used for Severe inflammatory or autoimmune conditions (specific indication unknown from phase 3 context).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}